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Introduction: Several data suggest that excitotoxicity due to excessive glutamatergic neurotransmission may be an
important factor in the mechanisms of motor neuron (MN) death occurring in amyotrophic lateral sclerosis (ALS).
We have previously shown that the overactivation of the Ca2+-permeable α-amino-3-hydroxy-5-methyl-4-isoxazole
propionate (AMPA) glutamate receptor type, through the continuous infusion of AMPA in the lumbar spinal cord of
adult rats during several days, results in progressive rear limb paralysis and bilateral MN degeneration. Because it
has been shown that energy failure and oxidative stress are involved in MN degeneration, in both ALS and
experimental models of spinal MN degeneration, including excitotoxicity, in this work we tested the protective
effect of the energy substrates pyruvate and β-hydroxybutyrate (βHB) and the antioxidants glutathione ethyl ester
(GEE) and ascorbate in this chronic AMPA-induced neurodegeneration.
Results: AMPA infusion induced remarkable progressive motor deficits, assessed by two motor tasks, that by day
seven reach bilateral rear limb paralysis. These effects correlate with the death of >80% of lumbar spinal MNs in the
infused and the neighbor spinal cord segments, as well as with notable astrogliosis in the ventral horns, detected
by glial fibrillary acidic protein immunohistochemistry. Co-infusion with pyruvate or βHB notably prevented the
motor deficits and paralysis, decreased MN loss to <25% and completely prevented the induction of astrogliosis. In
contrast, the antioxidants tested were ineffective regarding all parameters analyzed.
Conclusions: Chronic progressive excitotoxicity due to AMPA receptors overactivation results in MN death and
astrogliosis, with consequent motor deficits and paralysis. Because of the notable protection against these effects
exerted by pyruvate and βHB, which are well established mitochondrial energy substrates, we conclude that deficits
in mitochondrial energy metabolism are an important factor in the mechanisms of this slowly developed
excitotoxic MN death, while the lack of protective effect of the antioxidants indicates that oxidative stress seems to
be less significant factor. Because excitotoxicity may be involved in MN degeneration in ALS, these findings suggest
possible preventive or therapeutic strategies for the disease.
Keywords: AMPA, Amyotrophic lateral sclerosis, Antioxidants, Energy substrates, Excitotoxicity, Motor neurons,
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Amyotrophic lateral sclerosis (ALS) is a lethal neurode-
generative disorder characterized by the death of the upper
motor neurons (MNs) in the motor cortex and the lower
ones in the brain stem and the spinal cord. ALS patients
develop a progressive muscle paralysis and there is still no* Correspondence: rtapia@ifc.unam.mx
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article, unless otherwise stated.effective treatment. About 10% of ALS cases involve genetic
alterations and are therefore termed familial ALS, but the
etiology of the remainder 90%, sporadic ALS, is still largely
unknown. Among the many factors that have been involved
in the mechanisms of MN degeneration are glutamate
receptor-mediated excitotoxicity, oxidative stress, mitochon-
drial dysfunction, neuroinflammation, immune-mediated
processes, protein aggregation and axonal transport alter-
ations [1,2], but there is still no satisfactory explanation of
why such factors damage predominantly MNs.ioMed Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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volved in ALS pathogenesis, since morphological and
functional alterations in mitochondria of spinal MNs
and skeletal muscle of ALS patients have been described
[3-6], as well as mitochondrial swelling and vacuoliza-
tion in the spinal cord of transgenic mutant superoxide
dismutase 1 (SOD1) ALS mice [7,8]. In addition, isolated
mitochondria from the spinal cord of these mutant SOD1
mice showed decreased Ca2+ buffering capacity [8], and
dysfunction of oxidative phosphorylation and conse-
quently decreased ATP synthesis [9,10].
The excitotoxic process involves the entrance of Ca2+
through glutamate receptors, and the resulting disrup-
tion of Ca2+ homeostasis activates lytic enzymes, induces
the overproduction of reactive oxygen species and leads
to mitochondrial dysfunction and energy failure [2,11-13].
Work from our laboratory has shown that such excito-
toxic mechanism, mediated mainly by overactivation of
the Ca2+-permeable AMPA (α-amino-3-hydroxy-5-methy-
lisoxazole-4-propionate)-type receptors induces the death
of spinal MNs in the rat in vivo and that this results in
progressive paralysis. Acute or chronic infusion of AMPA
in the lumbar spinal cord, by means of microdialysis
[14,15] or osmotic minipumps [16], respectively, results in
MN degeneration that correlated with motor alterations
and finally paralysis of the rear limbs, in 3–12 h after mi-
crodialysis or in 3–5 days after the implantation of the os-
motic pump. The acute MN death and ipsilateral paralysis
caused by AMPA microdialysis perfusion was prevented
or reduced by specific Ca2+-permeable AMPA receptor
antagonists and by intracellular Ca2+ chelators [15,17],
demonstrating the vulnerability of spinal MNs to the exci-
totoxic effect of Ca2+-permeable AMPA receptors activa-
tion in vivo, which had been previously reported only in
studies in neuronal cultures in vitro [18-20]. Using the
acute microdialysis procedure, which results in rapid ipsi-
lateral MN loss and motor alterations of the correspond-
ing rearlimb, we recently showed that among several
energy substrates and antioxidants tested, pyruvate and β-
hydroxybutyrate (βHB) notably protected against the exci-
totoxic effects of AMPA whereas the antioxidants tested
were ineffective. These results allowed us to conclude that
failure in mitochondrial energy metabolism was greatly in-
volved in this rapid MN death, and also permitted to es-
tablish a correlation between the number of dead MNs
and the degree of unilateral motor alterations [21]. None-
theless, in this microdialysis acute experiment AMPA is
perfused during 25 min and produces only unilateral par-
alysis, MN alterations and motor deficits that develop in
less than 6 h, whereas the chronic slow continuous ad-
ministration of AMPA through osmotic minipumps in-
duces bilateral rear limb paralysis that progresses slowly
along several days, also correlated with MN loss but ex-
tended to both ventral horns. Therefore, we considered ofinterest to evaluate the efficacy of the energy substrates
and the antioxidants to protect against the chronic AMPA
excitotoxic action. In addition, we correlated the protect-
ive effect along the progress of motor alterations with
the MN loss in the infused region and in the immediate
rostral region of the lumbar spinal cord, as well as with
the prevention of astrogliosis induced by AMPA.
Materials and methods
Adult male Wistar rats (280–300 g) were used in all ex-
periments and were handled in accordance with inter-
national standards of animal welfare and with approval
of the Institutional Committee for the Care and Use of
Laboratory Animals (Approval No. RTI21-14). Rats were
housed in a laboratory environment with a 12 h light/
dark cycle and with food and water ad libitum. Animals
showing complete paralysis and loss of the righting re-
flex within 15 s were sacrificed to avoid unnecessary suf-
fering and were not analyzed further.
Osmotic minipumps implantation
The implantation of the osmotic minipumps in the lum-
bar spinal cord was carried out essentially as previously
described [16] with the following modifications.
All drugs were dissolved in 0.1 M phosphate buffer,
pH 7.4. After some preliminary experiments with 7.5,
4.5, 3.5 and 1 mM AMPA (Tocris, Ellisville, MO, USA),
the latter concentration was chosen because it induced a
slow and progressive paralysis of the rear limbs along
several days, whereas the effect of the higher doses was
more rapid and severe. We tested the effect of the en-
ergy substrates pyruvate and βHB, and the antioxidants
ascorbate and glutathione ethyl ester (GEE) (Sigma-
Aldrich, Saint Louis, MO, USA) at concentration of
20 mM, based on our previous work with AMPA acute
administration [21]. GEE was used instead of glutathione
because it enters the cell more efficiently [22]. Osmotic
minipumps (Alzet model 2004, capacity ~250 μL, flow
rate 6 μl/day) were filled with one of the following solu-
tions: vehicle as control, 1 mM AMPA, AMPA + sodium
pyruvate, AMPA + DL-βHB sodium salt, AMPA +GEE,
AMPA + L-ascorbic acid, and AMPA + antioxidant mix-
ture (GEE + ascorbate), and they were incubated in ster-
ile saline solution at 37°C for 48 h for stabilization
before the implantation. The day of surgery rats were
anesthetized with isoflurane 1-2% in a 95% O2 + 5% CO2
mixture and placed in a stereotaxic spinal unit. A longi-
tudinal incision of the skin was made in the lumbar re-
gion and muscles surrounding the lumbar vertebrae
were retracted. A stainless-steel screw (3.7 mm long,
1 mm diameter) was inserted on the left side of the third
lumbar vertebra without reaching the surface of the
spinal cord to anchor the implant. A 1–2 mm diameter
hole was drilled at the same vertebrae and a small cut of
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probe (1 mm long, 0.5 I.D. x 0.8 O.D., VitroCom Inc.)
into the right dorsal horn of the spinal cord. The other
end of the cannula was connected through a plastic tube
to the osmotic minipump which was placed subcutane-
ously in the back of the rat, caudally to the skin incision.
The probe and the screw were fixed to the bone with
dental acrylic. At the end of the surgery, the skin inci-
sion was closed with surgical stainless-steel clips and
rats received a single i.m. dose of penicillin (50 U). After
recovering from anesthesia animals were kept in individ-
ual cages with water and food ad libitum until perfusion
for histological analysis. Neither the control nor the ex-
perimental animals showed signs of pain or suffering
during the time period studied, even during their per-
formance in the motor tests.
Assessment of motor function
Before surgery rats were trained to achieve 120 s on the
rotarod test (Columbus Instruments), in which rotation
started at 10 rpm and accelerated at 0.2 rpm/s, and also
to perform a PGE task, where the latency to climb a ver-
tical grid is scored. Three trials/day/rat were assessed in
each motor test. In addition, the hind paw footprint was
registered using non-toxic Chinese ink on the hind paws
of rats. Besides, holding up the tail we photographically
recorded the changes in the position of the rear limbs.
These motor evaluations were assessed daily five days
prior surgery until the seventh day, when animals were
anesthetized and perfused for histology.
Histology and immunohistochemistry
Seven days after osmotic pump implantation rats were
perfused and fixed for histological and immunohisto-
chemical analyses as previously described [16]. Briefly,
spinal cords were removed, postfixed 48 h at 4°C and
dehydrated with 20% and 30% sucrose solutions. Trans-
verse sections (45 μm thick) of the spinal cords were ob-
tained in a cryostat. Fifty serial slices at the site of the
cannula infusion (infused region) and the next fifty ros-
tral slices (rostral region) were obtained, so that the total
tissue analyzed was 2.25 mm length, about 2 lumbar seg-
ments each region. Alternate slices were stained with
cresyl violet or immunostained for neurofilament protein
SMI-32 and glial fibrillary acidic protein (GFAP). The
number of morphologically healthy MNs (i.e. large neu-
rons with a soma diameter >20 μm and distinguishable
nucleus, similar in appearance to those of the control
and intact rats) in both the ipsilateral and contralateral
ventral horns were counted in fifteen Nissl-stained
slices/rat/region and the values were averaged.
For immunohistochemistry, mouse polyclonal anti-
SMI-32 (1:500, Abcam), chicken anti-GFAP (1:1000,
Abcam), as markers of neurons and astrocytes, respectively;Texas-red-conjugated anti-mouse (1:200, Invitrogen) and
fluorescein-conjugated anti-chicken (1:200, Novex) anti-
bodies were used. Sections were mounted on silane-
covered slides and coverslipped with fluorescent mounting
medium (DAKO). Sections were visualized under epifluor-
escent microscopy and merged images of the overlay of
FITC and Texas Red channels were obtained with Image J
(NIH, Bethesda, USA). The cross-reactivity in the im-
munofluorescent technique was excluded by control slices
incubated in the absence of primary antibodies. There was
no immunostaining in these controls.
Statistics
The statistical analysis of the number of healthy MNs,
the rotarod and PGE performance was carried out using
ANOVA followed by a Tukey’s post hoc test. A value of
p <0.05 was considered statistically significant.
Results
Energy substrates exert better protection than
antioxidants against the AMPA-induced motor alterations
None of the control rats showed motor dysfunctions
(Figures 1 and 2) or histological damage (Figures 3, 4
and 5) at any time up to 7 days, the maximum period
studied. Perfusion of pyruvate, βHB, GEE or ascorbate
alone at 20 mM concentration (n = 3 per group) was
also innocuous (not shown). The chronic 7.5 mM
AMPA infusion in the lumbar spinal cord of rats in-
duced a gradual paralysis of the rear limbs in about
3 days [16]. As mentioned in Methods, in this work we
reduced the concentration from 7.5 mM to 1 mM in
order to extend the time of progression of symptoms.
AMPA induced a paralysis that began in the distal ipsi-
lateral rear limb (phalanges), ascending through the
tarsus until the entire limb; the same process occurred
with a short delay in the contralateral limb. This progres-
sion is shown in Figure 1 at days 1, 4 and 7. Quantitative
assessment of these motor alterations in the rotarod and
the paw grip endurance (PGE) test is shown in Figure 2,
with emphasis in the values at these days to show the cor-
relation with the position of the paws at these times.
Whereas control rats remained in the rotarod for the total
test period of 120 s, AMPA-infused animals fell at 73 s at
day 1, 31–41 s at days 2–5 and 21 s at day 7. In the PGE
task, control rats climbed always within 1 s whereas
AMPA-treated animals at day 1 took double time to climb
and then this time increased progressively until 7 s at day
4 and 10 s at day 7.
Perfusion of pyruvate and βHB partially prevented the
AMPA-induced rear limbs paralysis. As shown in Figure 1,
animals from these groups were able to partially control
the ipsilateral phalanges and there was only a slight weak-
ness in the contralateral ones, manifested by an incom-
plete tarsus footprint contralateral paw. Although the
Figure 1 Progressive alterations of the rear limbs induced by AMPA and protection by energy substrates. Representative posterior views of the
rear limbs (C, contralateral; I, ipsilateral) and hind paw footprints (red, ipsilateral; black, contralateral) at the initial (day 1), the middle (day 4) and
last day (day 7) of treatment. The AMPA-induced progressive alterations were prevented by pyruvate and βHB but not by ascorbate and GEE
alone (not shown) or in combination (antioxidant mixture).
Figure 2 Assessment by rotarod (A) and PGE (B) performance of the protection by energy substrates. Pyruvate and βHB significantly prevented
the notable motor deficits induced by AMPA in both motor tasks, whereas ascorbate improved the scores on the PGE test but not in the rotarod
and GEE was ineffective. Three trials/day/rat were assessed in each motor task. Grey bars highlight the initial, middle and last day of infusion, as
shown in Figure 1. Data are mean values ± SEM for the number of rats shown in parentheses. #p < 0.05; ###p < 0.001 vs the corresponding value
of the AMPA group.
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Figure 3 AMPA-induced MN degeneration and protection by energy substrates. Representative micrographs of the ventral horns of Nissl-stained
sections of the infused lumbar spinal cord region of rats treated as indicated, seven days after minipump implantation. AMPA induced an almost
complete loss of MN in the infused side (ipsilateral) and a less intense degeneration in the contralateral side, and both effects were clearly
prevented by pyruvate and βHB but not by ascorbate or GEE. Quantitative analysis is shown in Figure 4. Scale bar = 100 μm.
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scribed AMPA-induced paralysis, its protective effect
was highly significant, attaining 91 s in the rotarod per-
formance at day 1, and then 66–76 s from day 4 to 7
(Figure 2A). In the PGE task pyruvate was very efficient,
since the time to climb was only 2–3 s during the whole
observation period, whereas βHB was less effective from
days 4–7, with climbing times of 4–5 s (Figure 2B).
In contrast to the notable protective effect of pyruvate
and βHB, neither GEE or ascorbate, alone or in combin-
ation, prevented the AMPA-induced motor deficits ob-
served in the rotarod. In these animals the times to fall
were similar or even lesser (days 1 and 4) than those
shown by the AMPA group during the whole period of
observation (Figure 2A). In the PGE test (Figure 2B),
GEE was also totally ineffective during all observation
period, but ascorbate partially protected, especially dur-
ing the first three days, where the time to climb was
similar to those with pyruvate and βHB. However, when
ascorbate was co-infused with GEE the protection dur-
ing the first three days was diminished (Figure 2B), as
shown also by the complete paralysis observed in the ip-
silateral rear limb in these animals (Figure 1).Figure 4 Quantitative analysis of MN loss in each experimental group. Num
the infused spinal cord region and in the adjacent rostral region of rats tre
and βHB notably prevented the AMPA-induced MN degeneration in the ip
and GEE, alone or in combination (antioxidant mixture) were ineffective
values ± SEM for the following number of rats in each group: control 7; AMPA
AMPA + antioxidants mixture 8. *p < 0.05, **p < 0.01, ***p < 0.001 vs the corre
the corresponding side of the AMPA group.Energy substrates reduced the AMPA-induced MN
degeneration
As described in Methods, we analyzed two regions of
the lumbar spinal cord (about two lumbar segments for
each region). The infused region refers to the area where
the cannula was implanted and the rostral region refers
to the next rostral segments. We analyzed both regions
because we found a differential effect of AMPA depend-
ing of its proximity to the probe. This pattern of damage
correlates, as explained in the Discussion, with the pro-
gression of the bilateral paralysis.
As shown in Figures 3 and 4, the infusion of AMPA
resulted at day 7 in an almost total loss of MNs (95%) in
the ipsilateral horn and a reduction of 60% in the
contralateral horn in the infused region, while in the ros-
tral region the degeneration was also notable in both
horns but less severe. The infusion of pyruvate and βHB
significantly reduced the MNs loss in the infused region
to 40%-50% in the ipsilateral horn and to only 10%-15%
in the contralateral side. The protection by both sub-
strates was also evident in the rostral region, where the
number of healthy MNs was similar to the values in the
control rats, especially in the contralateral horn. Theber of healthy MNs in the ipsilateral and contralateral ventral horns in
ated as indicated, seven days after minipump implantation. Pyruvate
silateral horn in both the infused and rostral regions, whereas ascorbate
. Fifteen histological slices/rat/region were analyzed. Data are mean
16; AMPA + Pyr 10; AMPA + βHB 10; AMPA + GEE 7; AMPA + ascorbate 8;
sponding side of the control group; #p < 0.05, ##p < 0.01, ###p < 0.001 vs
Figure 5 AMPA induced intense astrogliosis that was prevented by energy substrates. Representative immunohistochemistry of SMI-32 (red) and
GFAP (green) of the ipsilateral and contralateral ventral horns at the infused spinal cord region of rats treated as indicated, seven days after
minipump implantation. Note that in addition to the loss of MNs, AMPA induced a notable astrogliosis in both ipsilateral and contralateral ventral
horns, and that this effect, as that on MN, was prevented by pyruvate and βHB but not by ascorbate and GEE, alone or combined (antioxidants
mixture). Micrographs of the ascorbate or GEE alone groups (not shown) are very similar to those shown with the mixture. Fifteen slices/rat were
analyzed (7 rats per group). Scale bar = 50 μm.
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tect the spinal MNs in both regions, but ascorbate alone
or in combination with GEE slightly reduced the number
of MNs death, particularly in the contralateral horn of
the infused region; these changes, however, were not sig-
nificant (Figure 4).
Figure 5 shows that the loss of MN produced by
AMPA in the infused region was accompanied by a re-
markable astrogliosis, as detected by GFAP immunore-
activity, in both the ipsilateral and contralateral horns.
Similarly to the protection of MN, both energy sub-
strates tested almost completely prevented the glial re-
activity in the contralateral horn and clearly reduced it
in the ipsilateral side. In contrast, the GFAP immunore-
activity in the groups treated with AMPA + antioxidants
alone or in combination was not different from the
AMPA group. These results were reproduced in each of
the 7 rats treated in each group of animals and quantita-
tive analysis was not carried out.
Discussion
In this work we show that the spinal MN death and
astrogliosis induced by the continuous slow infusion of
AMPA are prevented by pyruvate and βHB, and in one
of the motor parameters studied by ascorbate, but not
by GEE. Although the protection by the energy sub-
strates was not complete, the number of protected
MNs was enough to notably prevent the progression
of the AMPA-induced motor deficits. These results
show a clear correlation between the progress of
motor alterations and significantly reduced MN loss
and astrogliosis.The AMPA-induced paralysis started in the ipsilateral
phalanges and extended with time to the upper regions
of the rear limb and to the contralateral side. This
suggests that progression of the effects is due to a slow
continuous diffusion of AMPA, explaining the larger
damage in the infused region as compared with the ros-
tral one. Because the infusion cannula was located be-
tween L3 and L4 segments of the spinal cord, the
nearest MNs to the probe, that innervate the extensor
digitorum that controls the phalanges movement are
probably the first ones to receive AMPA and to degener-
ate, and then AMPA diffuses to affect MNs in the rostral
region innervating upper limb muscles. The delay in the
appearance of symptoms in the contralateral side is
probably due also to the diffusion of the drug.
As mentioned in the Introduction, we have previously
reported that pyruvate and βHB protected against the
rapid deleterious action of the perfusion of AMPA dur-
ing 25 min by reverse microdialysis, which induces uni-
lateral paralysis and MN death in 3–12 h [21]. This
acute effect allows just a restricted analysis of motor al-
terations and leaves open the question of whether these
energy substrates are effective when the degeneration
process is much slower, as it occurs in the osmotic
pump continuous infusion procedure used in the present
work. A therapeutic effect of oral administration of
pyruvate was also reported in the mutant G93A-SOD
ALS mice [23], although in these transgenic mice daily
i.p. administration of pyruvate failed to delay the onset
and motor decline [24]. Pyruvate or βHB also protected
spinal MNs from mechanical damage [25], as well as
striatal or hippocampal neurons from oxidative stress
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ever, this is the first report of protection by pyruvate and
βHB in a non-genetic model of spinal MN degeneration
that correlated with the progression of motor impair-
ment during several days.
It is noteworthy that there was no significant differ-
ence among the protective effect produced by pyruvate
and βHB (tested at the same 20 mM concentration),
thus suggesting that these substrates share a neuropro-
tective mechanism. A possible interaction of pyruvate
and βHB with AMPA to explain the protection is im-
probable, because, judging from the structure of these
molecules it is difficult to envisage the possibility of such
interaction, especially considering that it should be oc-
curring with both substrates and these molecules differ
considerably. In addition, in our previous work using mi-
crodialysis [15,21], pyruvate and βHB perfusion started
60 min before AMPA and still protected. Furthermore,
we have shown that pyruvate and βHB are also good
protectors against glutamate-mediated excitotoxicity in
the hippocampus, in an in vivo model that does not use
AMPA but neurodegeneration is induced by stimulation
of glutamate release by 4-aminopyridine [28]. On the
other hand, these substrates share an important role in
energy metabolism. It is widely known that pyruvate is
the end product of glycolysis that can be oxidized by
mitochondria driving the synthesis of ATP [29]. Pyruvate
can also be taken by astrocytes and released as lactate to
serve as energy substrate to neighboring neurons. βHB
is a ketone body, a water-soluble mitochondrial fuel, that
can be used by neurons when its concentration increases
in the nervous system [30,31]. It is probably through
these energy-linked mechanisms that pyruvate and βHB
protect MN. In support of this interpretation, in cul-
tured neurons these substrates protect against the exci-
totoxic damage produced by NMDA or glutamate, by
stimulating the mitochondrial respiratory capacity and
thus improving energy production [32-36], thus suggest-
ing that in vivo they act through such mechanism. How-
ever, the protective effect of pyruvate and βHB has also
been associated to the ability of α-ketoacids to neutralize
H2O2 in a decarboxylating reaction. In cell cultures
pyruvate protected neuroblastoma and striatal neurons
exposed to H2O2 by diminishing the production of react-
ive oxidative species (ROS) [37,38], and βHB protected
neuronal cultures exposed to kainate or glutamate also
by reducing mitochondrial ROS production [33,34]. Im-
provement of the mitochondrial antioxidant defenses by
MitoQ [39] or by the overexpression of antioxidant en-
zymes [40] also protected MNs from neurodegeneration
induced by mutant G93A SOD1. Nevertheless, our re-
sults with ascorbate and GEE, an enzymatic cofactor and
potent antioxidant, and one of the major antioxidant
defenses of the cell, respectively, show that thesecompounds were ineffective, except for some improve-
ment in the PGE task with ascorbate alone or in com-
bination with GEE, which however cannot be correlated
with a protection against MN loss. Thus, although a role
of oxidative stress cannot be completely discarded, espe-
cially in the mutant SOD-linked MN degeneration, our
results indicate that this mechanism is not the predom-
inant factor in the MN death induced by chronic excito-
toxicity, in agreement with our previous results with the
acute infusion of AMPA [21].
An important factor in ALS appears to be a non-cell
autonomous neuron death in which other cellular types,
mainly glial cells, may play a role [41]. In this respect,
our results show that AMPA induced a notable reactive
astrocytosis that was, similarly to MN loss, prevented by
the energy substrates but not by the antioxidants, sug-
gesting that it is a consequence of MNs death rather
than a direct effect of AMPA.
Conclusion
This work shows that mitochondrial energy substrates
protect spinal MNs from the neurotoxic cascade trig-
gered by chronic excitotoxicity due to AMPA receptors
overactivation, whereas antioxidants were not effective.
We conclude that deficits in mitochondrial energy me-
tabolism are an important factor in the mechanisms of
this excitotoxic MN death in the spinal cord, while the
role of oxidative stress is less significant. Because
glutamate-mediated excitotoxicity has been postulated
as a causative factor in MN degeneration in sporadic
ALS, these findings suggest possible preventive or thera-
peutic strategies for the disease.
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